Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials
Alzheimer’s disease is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual decline in intellectual ability. The accumulation of beta-amyloid (Aβ) peptides is assessed to be one of the essential neuropathological pillars of the disorder, and its dishomeostasis plays an essential
A Novel PSEN1 Variant Leading to Posterior Cortical Atrophy: A Case Report
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects millions of people worldwide. The disease is characterized by the deposition in the brain of amyloid-β (Aβ) plaques and neurofibrillary tangles, mainly
A Case Report of a 37-Year-Old Alzheimer’s disease Patient with Prominent Striatum Amyloid Retention
The amyloid deposition has long been considered one of the pathognomonic markers of Alzheimer’s disease (AD). Moreover, disruption in the amyloid hypothesis has been frequently discussed as an important target of intervention
Neuroimaging in Alzheimer’s disease for Early Diagnosis: A Comprehensive Review
Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is the most common cause of dementia in older adults, distinguished by neurofibrillary tangles (NFTs) and neurotic plaques formed as a result of the accumulation of amyloid-beta (Aβ) peptides, most commonly in the neocortical structures and medial temporal lobe of the brain. Advanced age is the single most significant risk factor for AD. Symptoms generally appear after the age of
Prefrontal EEG slowing, synchronization, and ERP peak latency in association with predementia stages of Alzheimer’s disease
Dementia is a group of neurodegenerative disorders that affect human cognition and behaviors, like the decline in memory, changes in personality and behavior, and impairment in reasoning and language ability. Alzheimer’s disease (AD) is the main cause of
Neural biomarker diagnosis and prediction to mild cognitive impairment and Alzheimer’s disease using EEG technology
Alzheimer’s disease (AD) is the leading cause of dementia, accounting for an estimated 60-80% of cases worldwide. Presently, there is no effective treatment for AD and only very limited medicines show the potential for delaying the progression of this neurodegenerative disease at its early stage. On the other hand, amnestic mild cognitive impairment